Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers

Inclusion criteria

• Willing to sign informed consent before initiating any trial related procedures
• BMI: 19.0-25.0 kg/m2
• Fasting plasma glucose: 3.9-6.1 mmol/L
• Trial participant is judged to be in good health on the basis of their medical history, physical examination, ECG, and routine laboratory data

Exclusion criteria

• Any clinically significant disease history, in the opinion of the Investigator, of systemic or organ disease
• Clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening
• Any regular use of prescription or nonprescription drugs, including mega-vitamin or herbal supplement regimens that cannot be stopped at least two weeks prior to start of treatment and for the duration of the trial
• Currently a smoker (more than one cigarette per day or equivalent)
• Use of grapefruit or grapefruit juice within 7 days of trial product dose administration
• Blood donation, surgery or trauma with significant blood loss (400 mL) within the last 2 months prior to trial product dose administration
• Recent history (within the last 2 years) of drug or alcohol abuse
• Known or suspected allergy to trial product or any of the excipients or a history of multiple and/or severe allergies to drugs or foods or of severe anaphylactic reactions
• Subject has taken an investigational drug in another clinical trial within the last 4 weeks.
• Recent history (within the last 3 month) of nausea, diarrhea or gastrointestinal complaints
• History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose additional risk in administering trial product to the trial participant